Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
| Revenue (TTM) | $2.50B |
| Gross Profit (TTM) | $2.40B |
| EBITDA | $1.03B |
| Operating Margin | 40.70% |
| Return on Equity | 44.30% |
| Return on Assets | 23.50% |
| Revenue/Share (TTM) | $9.77 |
| Book Value | $7.50 |
| Price-to-Book | 9.13 |
| Price-to-Sales (TTM) | 6.80 |
| EV/Revenue | 6.42 |
| EV/EBITDA | 15.53 |
| Quarterly Earnings Growth (YoY) | 23.20% |
| Quarterly Revenue Growth (YoY) | 10.20% |
| Shares Outstanding | $244.01M |
| Float | $209.83M |
| % Insiders | 1.87% |
| % Institutions | 108.59% |
Volatility is currently expanding
Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Exelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances.
The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.
Bristol Myers Squibb TodayBMYBristol Myers Squibb$61.20 -0.28 (-0.45%) As of 01:50 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$42.52▼$68.64Dividend Yield4.12%P/E Ratio13.48Price Target$65.50Add to WatchlistGLP-1 agonists may have taken up most of the attention when it comes to game-changing drugs in the last couple of years, but the oncology landscape is heating up as well, and investors may see a transformation for some long-standing firms in the space.
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EXEL and any ticker you trade — then tracks every position and per-strategy win rate.
